ITK/CRBN PROTAC Binding Detection Kit: The Core Tool for Targeted Degradation Research in Sepsis-Associated Neuroinflammation

Author: Senior Product Manager of UA Views：8

This article systematically elucidates the molecular mechanism by which ITK participates in sepsis-induced depressive-like behaviors through regulating the Th17/Treg balance, focusing on the pathological role of ITK in sepsis-related neuroinflammation and its potential as a target for degradation research. It analyzes the regulatory role of the ITK signaling pathway in oxidative neuroinflammation and antioxidant defense, and explores the novel approach provided by CRBN-based PROTAC technology for targeted degradation of ITK.

Recent Advances
Product Information

Recent Advances

ITK/CRBN PROTAC Binding Assay Kit: A Core Tool for Targeted Degradation Research in Sepsis-Associated Neuroinflammation

Summary
This article systematically explores the pathological role of ITK in sepsis-associated neuroinflammation and its potential as a target for degradation. It elucidates the molecular mechanisms by which ITK regulates the Th17/Treg balance in sepsis-induced depressive-like behaviors, analyzes the regulatory role of ITK signaling in oxidative neuroinflammation and antioxidant defense, and discusses the novel approach provided by CRBN-based PROTAC technology for targeted ITK degradation.

I. Clinical Challenges of Sepsis-Associated Central Nervous System Dysfunction

Sepsis affects millions worldwide and is associated with multi-organ dysfunction, a major cause of increased morbidity and mortality. Sepsis is linked to various disorders, including dysfunction of the lungs, liver, and central nervous system. Sepsis-associated central nervous system dysfunction often leads to multiple psychiatric issues, including depression. Sepsis in the ICU is one of the leading causes of death and morbidity globally. The interaction between peripheral immune cells (e.g., Th17 cells) and the central nervous system during sepsis may contribute to various neurological consequences. Sepsis survivors are associated with behavioral/psychiatric disturbances such as depression, anxiety, delirium, loss of consciousness, and cognitive impairment in nearly 70% of critically ill patients. Therefore, exploring key regulatory molecules in sepsis-associated neuroinflammation and developing targeted intervention strategies hold significant clinical importance.

II. The Central Role of ITK in Th17 Cell Differentiation and Sepsis-Induced Neuroinflammation

IL-17A is one of the key cytokines expressed and secreted by Th17 cells. Studies report that Th17 cells are involved in the pathogenesis of depression and anxiety in humans and animals. A protein tyrosine kinase that plays a critical role in controlling Th17 cell development/differentiation is ITK. ITK is a member of the Tec kinase family and plays a canonical role in T lymphocyte development and differentiation. Research indicates that sepsis activates ITK signaling in both peripheral and central nervous systems—increased ITK activation in CD4+ T cells is reflected by the elevated percentage of p-ITK+ CD4+ T cells in sepsis-surviving mice. Additionally, ITK protein levels are also elevated in the cerebral cortex of sepsis-surviving mice. These findings suggest that ITK signaling is activated in both CD4+ T cells and the central nervous system of sepsis-surviving mice, indicating that ITK may be a key molecular node linking peripheral immune dysregulation with central neuroinflammation.

III. Molecular Mechanisms of ITK in Regulating Th17/Treg Balance and Oxidative Neuroinflammation

Regarding Th17-related signaling, results show elevated levels of IL-17A, p-STAT3, and p-NF-κB in peripheral CD4+ T cells. The sepsis-induced increase in Th17-related parameters is attenuated by ITK inhibitors. In the cerebral cortex, IL-17A levels are elevated, correlating with increased p-NF-κB protein levels. ITK inhibitors significantly reduce sepsis-induced IL-17A signaling. These data suggest that ITK activation is associated with elevated IL-17A levels in both peripheral and central nervous systems.

In terms of oxidative neuroinflammation, data show increased MPO activity, iNOS, and lipid peroxides in the cerebral cortex of septic mice. ITK inhibitor treatment leads to a significant downregulation of oxidative markers in the cerebral cortex of sepsis-surviving mice. Furthermore, IL-6 and MCP-1 mRNA levels are elevated in the cerebral cortex of sepsis-surviving mice, and ITK inhibitors substantially reduce the sepsis-associated elevation of neuroinflammatory mediators in the central nervous system. These results indicate that ITK inhibition has the potential to attenuate sepsis-induced oxidative and neuroinflammatory mediators.

In Treg-related signaling, ITK also regulates the development of Treg cells. Data show that IL-10 and Foxp3 are elevated in peripheral CD4+ T cells of sepsis-surviving mice, and Treg cells are further increased by ITK inhibitors in these mice. Additionally, IL-10 and Foxp3 mRNA levels are elevated in the cerebral cortex of sepsis-surviving mice treated with ITK inhibitors. These findings suggest that ITK inhibition upregulates Treg-related signaling in both peripheral and central nervous systems, potentially alleviating sepsis-induced neuroinflammation.

Regarding antioxidant defense, the Nrf2/HO-1 signaling pathway is dysregulated in the cerebral cortex, as evidenced by reduced Nrf2 nuclear translocation in septic mice. Nrf2-induced antioxidant enzymes are dysregulated in the cortex, with decreased HO-1 and SOD-2 mRNA levels in sepsis-surviving mice. ITK inhibitors correct the sepsis-induced disruption of Nrf2 signaling, reflected by the restoration of Nrf2 nuclear translocation in the cerebral cortex.

IV. The Ameliorative Effects of ITK Inhibition on Sepsis-Induced Depressive-Like Behaviors

Sepsis is known to induce depressive-like behaviors during recovery. Studies show that sepsis-surviving mice exhibit depressive-like behaviors—increased immobility time in the tail suspension test, increased marble-burying behavior, and reduced sucrose preference. ITK inhibitors reverse sepsis-induced depressive-like behaviors, manifested as reduced immobility time and decreased marble-burying behavior. Furthermore, ITK inhibitors counteract the sepsis-induced reduction in sucrose preference. These data indicate that ITK inhibition improves sepsis-induced depressive-like states. This study is the first to demonstrate that early intervention with ITK inhibitors may limit sepsis-induced neuroinflammation and depression by modulating the Th17/Treg balance, potentially improving long-term survival and outcomes in sepsis patients.

V. The Novel Approach Provided by PROTAC Technology for Targeted ITK Degradation

Proteolysis-targeting chimeras (PROTACs) utilize the ubiquitin-proteasome system to direct target proteins to the proteasome for degradation. Unlike traditional small-molecule inhibitors that block protein function by occupying active sites, PROTAC molecules form a ternary complex by binding the target protein at one end and recruiting an E3 ligase at the other, mediating polyubiquitination and subsequent degradation of the target protein.

For the ITK target, PROTAC technology offers a degradation strategy independent of kinase activity inhibition. ITK not only has kinase-dependent functions but also participates in regulating the Th17/Treg balance and neuroinflammatory signaling networks. While traditional ITK inhibitors primarily target its kinase activity, PROTACs can completely eliminate ITK's multifunctional roles through protein degradation. CRBN-based PROTAC molecules recruit the CRBN E3 ligase to achieve targeted ITK degradation, providing a new strategic direction for intervening in sepsis-associated neuroinflammation. The ability to form ternary complexes is a critical parameter determining PROTAC degradation efficiency, making the establishment of efficient and reliable binding assays essential at this stage.

VI. Conclusion

In practical applications of ITK-targeted degradation research, high-quality binding assay reagents are key to ensuring data reliability and experimental reproducibility. To meet the needs of evaluating ITK/CRBN PROTAC ternary complexes, UniOne offers the UniOne® TR-FRET Human ITK/CRBN PROTAC Binding Kit. This product is based on TR-FRET detection technology and features the following core characteristics: leveraging the long fluorescence lifetime of lanthanide donors to effectively reduce background interference through time-resolved detection; a homogeneous operation mode requiring no washing or separation steps, compatible with high-throughput formats in 96- and 384-well plates; excellent signal stability, supporting batch processing and flexible time windows; and suitability for quantitative detection of PROTAC-induced ternary complex formation between ITK and CRBN. This kit is applicable for screening and ranking the bridging activity of ITK-targeted PROTAC molecules, linker optimization and structure-activity relationship analysis, and CRBN ligand selectivity evaluation.

ITK, as a key kinase regulating the Th17/Treg balance and sepsis-associated neuroinflammation, has been gradually elucidated in its molecular mechanisms involving IL-17A signaling, oxidative neuroinflammation, and antioxidant defense dysregulation in sepsis-induced depressive-like behaviors. CRBN-based PROTAC technology provides a novel intervention pathway by inducing selective degradation of ITK protein, completely eliminating both its kinase-dependent and kinase-independent functions. The UniOne® TR-FRET Human ITK/CRBN PROTAC Binding Kit offers a reliable tool for binding assays of ITK-targeted PROTAC molecules, continuously driving innovation in the field of targeted therapy for sepsis-associated neuroinflammation.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next